PLI’s Health Care Technology 2024

PLI’s Health Care Technology 2024

Hybrid
Speaking Engagement
Register

PLI’s Health Care Technology 2024 is a 1-day program that helps in-house attorneys at health care organizations, companies that develop health care technology, life science companies, and the private practice lawyers who advise them, understand the latest regulatory developments related to health care technology.

Partner Kirk Nahra will lead a session at this year’s program titled “Navigating the Latest Regulatory Developments in Health Care Technology” from 11:30 a.m. – 12:30 p.m. The session will examine concerns new technologies have raised with the regulation of data privacy in health care, as regulatory agencies are taking an aggressive look at the implications and risks of health care technology, particularly with mobile apps and other contexts where health related data is being used in advertising contexts. After completing this session, participants will have a greater understanding of:

  • How the HIPAA eco-system is changing with new technology
  • The rapidly growing landscape for FTC regulation of health care technology
  • How state privacy laws are complicating the health technology landscape
  • How privacy and consumer protection law are driving how AI will be regulated
  • Best practices for managing and mitigating risk in this rapidly changing environment

In-person and online attendance options are available.

Register today.

Read More About the Event

Speakers

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.